论文部分内容阅读
目的比较卡培他滨联合奥沙利铂(XELOX)方案与亚叶酸钙、5-氟尿嘧啶(5-FU)联合奥沙利铂(mFOLFOX6)方案在结直肠癌辅助化疗中的依从性。方法将124例根治性切除术后的Ⅱ、Ⅲ期结直肠癌患者随机分为两组,XELOX方案组(n=62):卡培他滨(capecitabine,Xeloda)1000mg/m2,2次/d,口服,第1天至第14d;奥沙利铂(oxaliplatin)130mg/m2,静脉滴注,持续3h,第1d;21d为1周期。mFOLFOX6方案组(n=62):亚叶酸钙(CF)200mg/m2,静脉滴注,第1d,5-FU前;5-FU 400mg/m2,静脉推注,第1d,2400mg/m2,静脉持续滴注46h;奥沙利铂85mg/m2,静脉滴注,持续3h,第1d;14d为1周期。比较两组按时化疗的患者、调整剂量患者和完成全部疗程的患者有无差异。结果 XELOX组和m FOLFOX组按时化疗率分别为82%和77%,差异无统计学意义;需要调整剂量的发生率分别为24%和13%,差异有统计学意义;完成足疗程率分别为92%和89%,差异无统计学意义。结论与mFOLFOX6方案相比,XELOX方案有较多患者需要调整奥沙利铂的剂量。
Objective To compare the compliance of capecitabine plus oxaliplatin (XELOX) regimen with leucovorin and 5-fluorouracil (5-FU) and oxaliplatin (mFOLFOX6) in adjuvant chemotherapy for colorectal cancer. Methods A total of 124 patients with stage II and III colorectal cancer after radical resection were randomly divided into two groups: XELOX group (n = 62): capecitabine (Xeloda) 1000mg / m2, twice daily , Orally, the first day to the first 14d; oxaliplatin 130mg / m2, intravenous infusion for 3h, 1d; 21d for a cycle. mFOLFOX6 regimen (n = 62): 200 mg / m2 calcium leucovorin (CF) 200 mg / m2 intravenous infusion on day 1 before 5-FU 5-FU 400 mg / m2 intravenous injection on day 1 2400 mg / m2 intravenous Continuous infusion of 46h; oxaliplatin 85mg / m2, intravenous infusion for 3h, 1d; 14d for 1 cycle. Compare two groups of patients on time chemotherapy, adjusting the dose of patients and complete the course of treatment of patients with or without differences. Results The time-to-response rates of XELOX group and m FOLFOX group were 82% and 77%, respectively. There was no significant difference between the two groups. The incidence of need for dose adjustment was 24% and 13%, respectively, with significant difference. 92% and 89%, the difference was not statistically significant. Conclusion Compared with the mFOLFOX6 regimen, more patients in the XELOX regimen need to adjust the dose of oxaliplatin.